)
Inari Medical (NARI) investor relations material
Inari Medical Jefferies London Healthcare Conference 2024 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic overview and growth drivers
Focused on venous thromboembolism (VTE) with two purpose-built platforms for PE and DVT, treating over 165,000 patients since 2016.
Expanding into four adjacent markets with unmet needs, leveraging similar purpose-built tools.
International expansion underway, now in 15+ markets across Latin America and Asia-Pacific, with growing contributions.
U.S. VTE market development and penetration
U.S. VTE market has a $6B TAM with 700,000 annual cases; only 8% currently treated with company’s platforms.
Majority of patients still managed conservatively; early stages of shifting to catheter-based interventions.
Long-term vision is to reach penetration rates similar to STEMI (90%+), moving away from lytic-based therapies.
Clinical evidence and impact
PEERLESS RCT showed FlowTriever superior to catheter-directed thrombolysis (CDT) in intermediate-risk PE, with immediate patient improvement and shorter hospital stays.
60% lower 30-day readmission rate for FlowTriever vs. CDT; potential $150M revenue opportunity from share shift.
Strong physician feedback and RCT-level evidence expected to accelerate adoption.
Ongoing trials: PEERLESS II (FlowTriever vs. anticoagulation), PERSEVERE (high-risk PE), and DEFIANCE (DVT).
- TimeTickerHeadlineOpen
- 6 FebEMBASSY
Record revenue, NOI, and distributions highlight strong growth and robust segment performance. - 6 FebCRI
Revenue fell and losses deepened, but ESA contracts and R&D projects drive future prospects. - 6 FebNVDA
AI-driven digital twins and real-time simulation will transform engineering and manufacturing. - 6 FebCRI
Revenue fell, losses deepened, and a major segment spin-off and capital raise are underway. - 6 FebTUPRS
Net income reached TRY 29.5 billion, with strong dividends and a robust net cash position. - 6 FebCPT
2025 results beat guidance; Sun Belt focus, asset sales, and share buybacks drive 2026 strategy. - 6 FebCRI
Q1 2025 saw record revenue, a return to profit, and strategic spin-offs for future growth. - 6 FebCRI
H1 2025 saw a return to profit, record revenues, and strong cash from major space projects. - 6 FebSCW
Q2 2025 revenue up 120% y/y, driven by record Asian contract and backlog growth. - 6 FebSCW
Revenue up 89% y/y, record backlog, and new strategy for European optical payload leadership.
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage
)
)